Filing Analysis
Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer and approved significant stock option grants for its executive team and board. The new CMO brings substantial experience from Genentech and Arcus Biosciences to lead the clinical development of PAS-004.
Red Flags
- Large-scale equity grants to existing management and directors (over 5.2 million shares total) following dilutive capital raises.
- The company's stock price is below $1.00 ($0.841), placing it at risk of Nasdaq minimum bid price non-compliance if it remains there.
Key Facts
- Dr. Kartik Krishnan appointed Chief Medical Officer effective May 1, 2026, with a base salary of $500,000.
- Dr. Krishnan previously served as CEO of OncoNano Medicines and CMO of Arcus Biosciences, and was involved in the FDA approval of Cotellic™ at Genentech.
- The Board approved massive stock option grants: 1,756,069 shares to CEO Dr. Tiago Reis Marques and 1,129,323 shares each to CFO Daniel Schneiderman and CMO Dr. Krishnan.
- The exercise price for all new options is $0.841 per share, the closing price on May 1, 2026.
- The filing explicitly states these grants were made to 'reflect the ownership impact of certain recent capital raises,' suggesting significant prior dilution.
Pasithea Therapeutics Corp. (KTTA) received a Nasdaq non-compliance notice on February 20, 2026 for failing to maintain the $1.00 minimum bid price requirement under Rule 5550(a)(2), with its stock trading below $1.00 for 30 consecutive business days. The company has an initial 180-day cure period through August 19, 2026, with a possible second 180-day extension, but the filing explicitly references a potential reverse stock split as a compliance mechanism — a significant red flag for micro-cap shareholders.
Red Flags
- Nasdaq minimum bid price non-compliance — stock trading below $1.00 for 30+ consecutive business days indicates severe price deterioration
- Potential reverse stock split mentioned as a cure mechanism, which typically destroys shareholder value in micro-caps
- Emerging growth company with sub-dollar stock price suggests capital-raising difficulties and possible cash burn concerns
- Dual compliance periods (up to 360 days total) suggest Nasdaq expects difficulty in regaining compliance organically
- Warrants outstanding (KTTAW) add dilution overhang, making price recovery harder
Key Facts
- Received Nasdaq non-compliance notice on February 20, 2026 for failure to meet $1.00 minimum bid price requirement (Rule 5550(a)(2))
- Company's common stock closing bid price was below $1.00 for 30 consecutive business days prior to the notice
- Initial 180-day compliance period granted, expiring August 19, 2026
- Company may be eligible for a second 180-day compliance period if it meets other listing requirements and notifies Nasdaq of intent to cure (e.g., via reverse stock split)
- No immediate delisting — compliance can be regained if bid price closes at or above $1.00 for 10 consecutive business days
- Company is an emerging growth company incorporated in Delaware, headquartered in Miami Beach, FL
- Listed on Nasdaq Capital Market; both common stock (KTTA) and warrants (KTTAW) are registered under Section 12(b)
- Par value of common stock is $0.0001 per share
- Filing signed by CEO Tiago Reis Marques